Deutsche Bank Aktiengesellschaft Cuts Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $25.00

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) had its price objective lowered by investment analysts at Deutsche Bank Aktiengesellschaft from $50.00 to $25.00 in a research note issued to investors on Tuesday,Benzinga reports. The brokerage presently has a "hold" rating on the biotechnology company's stock. Deutsche Bank Aktiengesellschaft's price objective indicates a potential upside of 14.53% from the company's current price.

Several other analysts also recently commented on SRPT. Barclays reduced their price objective on shares of Sarepta Therapeutics from $89.00 to $29.00 and set an "overweight" rating for the company in a research report on Tuesday. The Goldman Sachs Group restated a "neutral" rating and set a $29.00 price target on shares of Sarepta Therapeutics in a research note on Tuesday. Evercore ISI downgraded shares of Sarepta Therapeutics from an "outperform" rating to an "inline" rating and set a $50.00 target price for the company. in a research note on Thursday, May 8th. Scotiabank upgraded shares of Sarepta Therapeutics from a "sector perform" rating to a "sector outperform" rating and set a $80.00 target price on the stock in a research note on Friday, June 6th. Finally, Guggenheim dropped their target price on shares of Sarepta Therapeutics from $112.00 to $98.00 and set a "buy" rating for the company in a research report on Wednesday, May 7th. One investment analyst has rated the stock with a sell rating, eleven have given a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $74.13.

Sarepta Therapeutics Trading Up 4.2%

Shares of SRPT traded up $0.89 during trading hours on Tuesday, reaching $21.83. The stock had a trading volume of 9,231,252 shares, compared to its average volume of 3,016,078. The firm has a 50-day moving average of $45.69 and a 200 day moving average of $85.25. Sarepta Therapeutics has a 52 week low of $18.30 and a 52 week high of $173.25. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93. The company has a market cap of $2.15 billion, a P/E ratio of 17.46 and a beta of 0.61.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The biotechnology company reported ($3.42) earnings per share for the quarter, missing the consensus estimate of $2.20 by ($5.62). The firm had revenue of $744.86 million for the quarter, compared to analyst estimates of $685.75 million. Sarepta Therapeutics had a return on equity of 11.00% and a net margin of 7.43%. The firm's revenue for the quarter was up 80.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.73 earnings per share. On average, sell-side analysts expect that Sarepta Therapeutics will post 2.67 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Sarepta Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the stock. EP Wealth Advisors LLC grew its holdings in Sarepta Therapeutics by 2.2% in the 4th quarter. EP Wealth Advisors LLC now owns 4,988 shares of the biotechnology company's stock valued at $606,000 after buying an additional 105 shares during the last quarter. CIBC Asset Management Inc lifted its holdings in shares of Sarepta Therapeutics by 5.1% during the 4th quarter. CIBC Asset Management Inc now owns 2,851 shares of the biotechnology company's stock worth $347,000 after acquiring an additional 139 shares during the period. PNC Financial Services Group Inc. boosted its holdings in Sarepta Therapeutics by 5.3% during the fourth quarter. PNC Financial Services Group Inc. now owns 2,891 shares of the biotechnology company's stock valued at $352,000 after purchasing an additional 145 shares in the last quarter. Virtus ETF Advisers LLC boosted its stake in Sarepta Therapeutics by 6.6% in the 4th quarter. Virtus ETF Advisers LLC now owns 2,809 shares of the biotechnology company's stock valued at $342,000 after buying an additional 174 shares in the last quarter. Finally, Steward Partners Investment Advisory LLC grew its holdings in shares of Sarepta Therapeutics by 164.4% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 312 shares of the biotechnology company's stock worth $38,000 after purchasing an additional 194 shares during the last quarter. Hedge funds and other institutional investors own 86.68% of the company's stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.